200 TECHNOLOGY SQUARE, CAMBRIDGE, MA
Financial Results, Press Release
Appoints Michael McDonnell to Board of Directors
Amendments to Articles of Incorporation or Bylaws, Shareholder votes
Reports First Quarter 2026 Financial Results and Provides Business Updates
Annual Report to Security Holders
Moderna Enters $950 Million Settlement Agreement with Arbutus/Genevant
Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates
Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
SC TO-I
Tender Offer Statement by Issuer
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Notice of Proposed Sale of Securities
Initial Statement of Beneficial Ownership
Amended Tender Offer Statement by Issuer
Submission Upload
Correspondence